<DOC>
	<DOCNO>NCT00299195</DOCNO>
	<brief_summary>The purpose study see drug call sulindac prevent development change mouth related oral pre-cancer growth ( oral epithelial dysplasia ) oral cancer . Sulindac anti-inflammatory drug already test people arthritis ( inflammation joint ) . This study do Memorial Sloan-Kettering Cancer Center New York , Amrita Institute Medical Sciences Research Center Cochin , India , Regional Cancer Centre ( RCC ) Trivandrum , India .</brief_summary>
	<brief_title>A Randomized Study Sulindac Oral Premalignant Lesions</brief_title>
	<detailed_description>Oral precancerous lesion ( OPL ) represent valuable model clinical trial tobacco relate cancer . However , due relatively low prevalence condition United States , subject accrual trial slow . Conversely , India , prevalence oral leukoplakia among high world . Indeed oral cancer , cause exposure tobacco smoke , alcohol betel nut quid , lead cause cancer death India . To date , effective treatment document randomize controlled clinical trial prevent malignant transformation leukoplakia . However , evidence non-steroidal anti-inflammatory drug ( NSAIDs ) prevent experimental animal head neck cancer , colon breast cancer human lend support promise NSAIDs chemoprevention oral cancer . The purpose protocol pilot multi-center chemoprevention trial sulindac , pan-cyclooxygenase ( COX ) inhibitor , oral leukoplakia international collaboration Memorial Sloan-Kettering Cancer Center ( MSKCC ) , New York , Regional Cancer Centre ( RCC ) Trivandrum , India Amrita Institute Medical Sciences ( AIMS ) , Kerala , India . Specifically , conduct 66 subject , 2-arm , double-blind , placebo-controlled randomize study sulindac 150 mg bid test clinical efficacy , safety molecular effect sulindac OPL OPL tissue . Oral leukoplakia subject enrol RCC , AIMS MSKCC , however , expect subject recruit AIMS due substantially high prevalence condition among Indian compare US population . MSKCC coordinate center trial , thus responsible aspect clinical trial design management . Our study team , collaboration Office Clinical Research Office Physician-in-Chief , spend considerable amount time effort develop comprehensive data safety monitoring ( DSM ) plan .</detailed_description>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Leukoplakia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukoplakia , Oral</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>For study Oral Premalignant Lesions ( OPL ) define lesion include atypical hyperplasia , atypical hyperkeratosis , leukoplakia , erythroplakia/erythroleukoplakia . Histology MUST confirm MSKCC pathologist participate site . An OPL may locate oral cavity , oropharynx . The subj histologically suspect confirmed index oral premalignant lesion , 12mm great size bx 'd past 6 wks . Each index lesion must either : An EARLY premalignant lesion define high risk indicate presence least one following : atypical cell mild dysplasia , hyperplastic leukoplakia highrisk site , lateral ventral tongue floor mouth OR An ADVANCED premalignant lesion define presence least one following : moderate dysplasia severe dysplasia ( exclude CIS ) The subj &gt; 18 yr age The subj 's life expectancy &gt; 12 wks Zubrod performance status 0 1 ( Appendix VIII ) . The subj meet follow lab eligibility criterion time exceed 4 wks prior randomization . Hemoglobin level 10g/dL woman 12g/dL men . WBC count &gt; 3,000 uL . Platelets count &gt; 125,000 uL . Total bilirubin &lt; = 1.5xULN AST ( SGOT ) ALT ( SGPT ) &lt; = 2.5 x ULN . BUN serum creatinine &lt; = 1.5 x ULN . If subj female childbearing potential ( woman consider childbearing potential least 2 yrs postmenopausal and/or surgically sterile ) , : use adequate contraception ( abstinence , IUD , birth control pill , spermicidal gel diaphragm condom ) since last menses use adequate contraception study , AND lactating , AND document negative serum pregnancy test within 14 d prior randomization . The subj 's history/use NSAIDs , aspirin , corticosteroid meet follow criterion : total oral/intravenous corticosteroid use &lt; 14 d within 6 mo Baseline visit , total inhale corticosteroid use &lt; 30 d within 6 mo Baseline visit , willing limit aspirin use &lt; = 120 mg po per ( typical cardioprotective dose India ) &lt; = 80 mg po per ( typical cardioprotective dose US ) duration study , willing abstain chronic use NSAIDs COX2 inhibitor duration study . Chronic use NSAIDs define frequency &gt; = 3 times/wk AND total 14 d yr . The subj discontinue chemopreventive therapy least 3 mos prior Baseline visit toxicity fully resolve . If applicable , subj counsel smoking cessation . If subject male , use adequate contraception study . The subject chemotherapy , immunotherapy , hormonal tx ( HRT menopause ) , RT within 3 wks Baseline visit . The subj recover acute toxic effect chemotherapy , immunotherapy , hormonal tx , RT . The subj need concurrent chemotherapy , radiotherapy , hormonal ( HRT menopause ) , immunotherapy time study . The subj history hypersensitivity sulindac , COX2 inhibitor , NSAIDs , salicylates . The subj diagnose treated esophageal , gastric , pyloric channel , duodenal ulceration . The subj history inv cancer within past 1 yr ( exclude nonmelanoma skin cancer situ cervical cancer ) . The subj chronic acute renal hepatic disorder significant bleed disorder condition , Institutional Principal Investigator 's opinion , might preclude study participation . The subj past history active inflammatory bowel disease ( eg . Crohn 's disease ulcerative colitis ) pancreatic disease . The subj receive investigational medication within 30 d Baseline visit schedule receive investigational drug course study . The subj , opinion Institutional Principal Investigator , appropriate candidate study participation . The subj participate study previously withdraw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Oral Leukoplakia</keyword>
	<keyword>Benign Neoplasms</keyword>
	<keyword>Chemoprevention</keyword>
	<keyword>Pan-cyclooxygenase ( COX ) inhibitor</keyword>
	<keyword>sulindac</keyword>
	<keyword>04-099</keyword>
</DOC>